Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

15.5%

33 terminated/withdrawn out of 213 trials

Success Rate

80.8%

-5.7% vs industry average

Late-Stage Pipeline

17%

37 trials in Phase 3/4

Results Transparency

42%

59 of 139 completed trials have results

Key Signals

20 recruiting59 with results26 terminated7 withdrawn

Enrollment Performance

Analytics

Phase 1
118(60.2%)
Phase 2
37(18.9%)
Phase 3
29(14.8%)
Phase 4
8(4.1%)
N/A
4(2.0%)
196Total
Phase 1(118)
Phase 2(37)
Phase 3(29)
Phase 4(8)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (213)

Showing 20 of 213 trials
NCT07409272Phase 3Recruiting

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Role: lead

NCT07475806Phase 2Recruiting

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Role: lead

NCT07488676Phase 1Recruiting

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Role: lead

NCT03364153Phase 2Completed

Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Role: lead

NCT05536297Phase 3Completed

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Role: lead

NCT07425574Recruiting

A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

Role: lead

NCT02960022Phase 2Recruiting

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Role: lead

NCT04225117Phase 2Active Not Recruiting

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Role: lead

NCT06779773Recruiting

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Role: lead

NCT05083481Phase 1Active Not Recruiting

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Role: lead

NCT07005154Phase 2Recruiting

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Role: lead

NCT07287995Phase 1Recruiting

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Role: lead

NCT06544642Phase 1Terminated

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome

Role: lead

NCT07417137Recruiting

A Natural History Study of Angelman Syndrome

Role: collaborator

NCT03288545Phase 1Terminated

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

Role: lead

NCT06812754Phase 2Completed

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause

Role: lead

NCT05719558Phase 1Recruiting

A Study of ASP1002 in Adults for Treatment of Solid Tumors

Role: lead

NCT07024615Phase 1Recruiting

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Role: lead

NCT03816163Phase 2Active Not Recruiting

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

Role: lead

NCT06901531Phase 3Recruiting

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Role: lead